Previous close | 0.1000 |
Open | 0.1000 |
Bid | 0.0500 |
Ask | 0.2000 |
Strike | 4.00 |
Expiry date | 2025-01-17 |
Day's range | 0.1000 - 0.1000 |
Contract range | N/A |
Volume | |
Open interest | 278 |
MALVERN, Pa., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder and Dr. Huma Qamar, MPH, CMI, Head of Clinical Development and Medical Affairs will participate in an in-person fireside chat moderated by Daniil Gataulin, PhD, Senior Bi
MALVERN, Pa., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Connie Collingsworth, former Chief Operating Officer of the Bill and Melinda Gates Foundation, will join the Company’s Business Advisory Board (BAB). The BAB was established in June 2023 to assist in driving public/private partnerships with
MALVERN, Pa., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will participate in a panel at the annual Cantor Fitzgerald Global Healthcare Conference taking place from September 26-28, 2023 in NYC. On the panel, Dr. Musun